Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2003

View Archived Issues

SkyePharma updates key product developments

New commercialization and development agreement for Velcade

Lilly Icos submits complete response to FDA for Cialis

Final phase II/III data confirms interim Onco TCS results

Fast track designation awarded to Avastin

FDA delays Estrasorb decision date

Chiesi files IND to advance Formoterol Modulite into clinic

Genmab files CTA to begin phase I/II trial of HuMax-EGFr

Genasense receives fast track designation in CLL

Oxytrex to be studied in phase III pivotal trial

FDA accepts the NDA for trospium

Sustained pain relief found with a new DHE formulation in acute migraine

New cPLA2 inhibitors and their use reported by Wyeth in recent patent

Antimicrobial peptides covered by IPF PharmaCeuticals patent

Toyama claims novel inhibitors of AP-1 transcription factor

Trials confirm the efficacy and safety of bortezomib in multiple myeloma and mantle cell lymphoma

Muscarinic M2/M3 receptor antagonists for urinary incontinence and other uses

The antisense therapeutic EN-101 superior to conventional AChE inhibitors in myasthenia gravis

MS&D designs 5-HT7 antagonists with utility in depression and sleep disorders

Similar pharmacokinetic profiles found for pregabalin in healthy subjects and chronic pain patients

Triazole-based antifungal agent prepared and tested at Meiji Seika

Liarozole granted E.U. orphan drug designation for congenital ichthyosis

Multinational phase III dexanabinol study opens enrollment in U.S.

Antisoma initiates enrollment in phase I study of R-1550 in breast cancer

Endovion shows promising results in preclinical and phase I studies

Phase II trial to evaluate Pentrix in prostate cancer

Benzothiazole-based inhibitor of Lck with good cellular activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...